The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
The mechanisms responsible for the evolution of steatosis towards NASH (non-alcoholic steatohepatitis) and fibrosis are not completely defined. In the present study we evaluated the role of CD4+ T-helper (Th) cells in this process. We analysed the infiltration of different subsets of CD4+ Th cells in C57BL/6 mice fed on a MCD (methionine choline-deficient) diet, which is a model reproducing all phases of human NASH progression. There was an increase in Th17 cells at the beginning of NASH development and at the NASH–fibrosis transition, whereas levels of Th22 cells peaked between the first and the second expansion of Th17 cells. An increase in the production of IL (interleukin)-6, TNFα (tumour necrosis factor α), TGFβ (transforming growth factor β) and CCL20 (CC chemokine ligand 20) accompanied the changes in Th17/Th22 cells. Livers of IL-17−/− mice were protected from NASH development and characterized by an extensive infiltration of Th22 cells. In vitro, IL-17 exacerbated the JNK (c-Jun N-terminal kinase)-dependent mouse hepatocyte lipotoxicity induced by palmitate. IL-22 prevented lipotoxicity through PI3K (phosphoinositide 3-kinase)-mediated inhibition of JNK, but did not play a protective role in the presence of IL-17, which up-regulated the PI3K/Akt inhibitor PTEN (phosphatase and tensin homologue deleted on chromosome 10). Consistently, livers of IL-17−/− mice fed on the MCD diet displayed decreased activation of JNK, reduced expression of PTEN and increased phosphorylation of Akt compared with livers of wild-type mice. Hepatic infiltration of Th17 cells is critical for NASH initiation and development of fibrosis in mice, and reflects an infiltration of Th22 cells. Th22 cells are protective in NASH, but only in the absence of IL-17. These data strongly support the potentiality of clinical applications of IL-17 inhibitors that can prevent NASH by both abolishing the lipotoxic action of IL-17 and allowing IL-22-mediated protection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD4 + T H 17 cells and CD8 + T cells have been shown to mediate NASH-associated liver fibrosis in both mice and humans (5-9).”
From NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis (2023) · cites this paper as [7]
In the citing paper
“Deficiency of this cytokine or its signalling components results in decreased hepatic accumulation of myeloid cells in models of NASH (7,52).”
From NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis (2023) · cites this paper as [7]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
The lineage decisions of helper T cells
Murphy, K. M., & Reiner, S. L. (2002) · Nature Reviews Immunology · doi:10.1038/nri954 · Cited by 1,674
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells
Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1767 · Cited by 1,079
Nakae, S., Komiyama, Y., Nambu, A., Sudo, K., Iwase, M., Homma, I., Sekikawa, K., Asano, M., & Iwakura, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00391-6 · Cited by 1,052
Cited by
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Zhou, D., Pan, Q., Shen, F., Cao, H.-X., Ding, W.-J., Chen, Y.-W., & Fan, J.-G. (2017) · Scientific Reports · doi:10.1038/s41598-017-01751-y · Cited by 421
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Ruiz de Morales, J. M. G., Puig, L., Daudén, E., Cañete, J. D., Pablos, J. L., Martín, A. O., Juanatey, C. G., Adán, A., Montalbán, X., Borruel, N., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102429 · Cited by 338
T Cells in Fibrosis and Fibrotic Diseases
Zhang, M., & Zhang, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01142 · Cited by 330
Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond
Liu, R., & Nikolajczyk, B. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01587 · Cited by 303
Liver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases
Zhang, S., Gang, X., Yang, S., Cui, M., Sun, L., Li, Z., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678355 · Cited by 263
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
“Multiple experimental animal and in vitro studies report an increase in steatosis when administering IL-17, as well as a decrease in steatosis when blocking IL-17 functionality (29, 55, 64, 70).”
BackgroundInfluentialNon-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Molecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2025) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 169
Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights
Stephenson, K., Kennedy, L. L., Hargrove, L. A., Demieville, J., Thomson, J., Alpini, G. D., & Francis, H. (2017) · Gene Expression · doi:10.3727/105221617x15093707969658 · Cited by 164
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 111
CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease
Breuer, D. A., Pacheco, M. C., Washington, M. K., Montgomery, S. A., Hasty, A. H., & Kennedy, A. J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00040.2019 · Cited by 113
CD4+ T cell activation and inflammation in NASH-related fibrosis
Zhou, Y., Zhang, H., Yao, Y., Zhang, X., Guan, Y., & Zheng, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967410 · Cited by 106
Malaisé, Y., Menard, S., Cartier, C., Gaultier, E., Lasserre, F., Lencina, C., Harkat, C., Geoffre, N., Lakhal, L., Castan, I., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15196-w · Cited by 107
Psoriasis and Systemic Inflammatory Disorders
Tashiro, T., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084457 · Cited by 104
Liu, H., Zhan, X., Xu, G., Wang, Z., Li, R., Wang, Y., Qin, Q., Shi, W., Hou, X., Yang, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105384 · Cited by 106
Her, Z., Tan, J. H. L., Lim, Y.-S., Tan, S. Y., Chan, X. Y., Tan, W. W. S., Liu, M., Yong, K. S. M., Lai, F., Ceccarello, E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580968 · Cited by 97
IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases
Beringer, A., & Miossec, P. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.008 · Cited by 108
Luo, T., Wang, D., Zhao, Y., Li, X., Yang, G., & Jin, Y. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.156884 · Cited by 101
Paquissi, F. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01195 · Cited by 93
Paquissi, F. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00490 · Cited by 94
γδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming
Torres‐Hernandez, A., Wang, W., Nikiforov, Y., Tejada, K., Torres, L., Kalabin, A., Adam, S., Wu, J., Lu, L., Chen, R., et al. (2020) · Hepatology · doi:10.1002/hep.30952 · Cited by 80
Yan, M., Cui, Y., & Xiang, Q. (2025) · Theranostics · doi:10.7150/thno.106597 · Cited by 95
Simon, T. G., Trejo, M. E. P., McClelland, R. L., Bradley, R. D., Blaha, M. J., Zeb, I., Corey, K. E., Budoff, M. J., & Chung, R. T. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.01.046 · Cited by 89
Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 73
Immunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity
Gupta, G., Khadem, F., & Uzonna, J. E. (2019) · Cytokine · doi:10.1016/j.cyto.2018.09.004 · Cited by 69
TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop
Ahmed, H., Umar, M. I., Imran, S., Javaid, F., Syed, S. K., Riaz, R., & Hassan, W. (2021) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2021.104733 · Cited by 71
Zhou, D., Pan, Q., Liu, X., Yang, R., Chen, Y., Liu, C., & Fan, J. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13742 · Cited by 67
Wang, T., Ishikawa, T., Sasaki, M., & Chiba, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.822190 · Cited by 78
Hepatic Immune Microenvironment in Alcoholic and Nonalcoholic Liver Disease
Byun, J., & Yi, H. (2017) · BioMed Research International · doi:10.1155/2017/6862439 · Cited by 63
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
Chackelevicius, C. M., Gambaro, S. E., Tiribelli, C., & Rosso, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9096 · Cited by 57
Hatasa, M., Yoshida, S., Takahashi, H., Tanaka, K., Kubotsu, Y., Ohsugi, Y., Katagiri, T., Iwata, T., & Katagiri, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073728 · Cited by 64
Inflammation in MASLD progression and cancer
Kim, Y. S., Park, Y., Rho, H., Yao, T., Gao, B., & Hwang, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101414 · Cited by 75
Li, C., Yu, R., & Ding, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1026457 · Cited by 62
Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models
Ishioka, M., Miura, K., Minami, S., Shimura, Y., & Ohnishi, H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4393-x · Cited by 58
The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
Méndez‐Sánchez, N., Valencia-Rodríguez, A., Coronel-Castillo, C. E., Vera-Barajas, A., Contreras-Carmona, J., Ponciano‐Rodríguez, G., & Zamora‐Valdés, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.184 · Cited by 57
Vitamin A: too good to be bad?
Chen, G., Weiskirchen, S., & Weiskirchen, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186336 · Cited by 65
Imarisio, C., Alchera, E., Revanna, C. B., Valente, G., Follenzi, A., Trisolini, E., Boldorini, R. L., & Carini, R. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.020 · Cited by 49
Self-citationZhang, H., Jiang, Z., & Zhang, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.005 · Cited by 49
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
Torre, P., Motta, B. M., Sciorio, R., Masarone, M., & Persico, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.781567 · Cited by 53
Nascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 56
The roles of Th cells in myocardial infarction
Liu, J., Liu, F., Liang, T., Zhou, Y., Su, X., Li, X., Zeng, J., Qu, P., Wang, Y., Chen, F., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02064-6 · Cited by 50
Stress kinases in the development of liver steatosis and hepatocellular carcinoma
Cicuéndez, B., Ruiz-Garrido, I., Mora, A., & Sabio, G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101190 · Cited by 48
Immune–metabolic interactions in homeostasis and the progression to NASH
Hoogerland, J. A., Staels, B., & Dombrowicz, D. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.07.001 · Cited by 48
Marinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1599 · Cited by 43
Su, L., Wu, Z., Chi, Y., Song, Y., Xu, J., Tan, J., Cong, X., & Liu, Y. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.01.005 · Cited by 43
Van Herck, M. A., Vonghia, L., Kwanten, W. J., Julé, Y., Vanwolleghem, T., Ebo, D. G., Michielsen, P. P., De Man, J. G., Gama, L., De Winter, B. Y., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.010 · Cited by 43
Zai, W., Chen, W., Liu, H., & Ju, D. (2021) · Biomedicines · doi:10.3390/biomedicines9121912 · Cited by 44
Type 3 cytokines in liver fibrosis and liver cancer
Molina, M. F., Abdelnabi, M. N., Fabre, T., & Shoukry, N. H. (2019) · Cytokine · doi:10.1016/j.cyto.2018.07.028 · Cited by 39
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 46
The Interleukin-20 Cytokine Family in Liver Disease
Caparrós, E., & Francés, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01155 · Cited by 42
The role of the interleukin family in liver fibrosis
Zhang, Z., Wang, J., Li, H., Niu, Q. F., Tao, Y., Zhao, X., Zeng, Z., & Dong, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1497095 · Cited by 50
Olveira, A., Augustín, S., Benlloch, S., Ampuero, J., Suárez‐Pérez, J. A., Armesto, S., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., et al. (2023) · Life · doi:10.3390/life13020419 · Cited by 44
Abdelghany, A. H., Basalamah, M. A., Idris, S., Ahmad, J., & Refaat, B. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1040-4 · Cited by 38
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
Functional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links
Chakraborty, D., & Wang, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118507 · Cited by 36
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Insights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Van Herck, M. A., Vonghia, L., Kwanten, W. J., Vanwolleghem, T., Ebo, D. G., Michielsen, P. P., De Man, J. G., Gama, L., De Winter, B. Y., & Francque, S. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01711 · Cited by 30
Liu, Y., Hao, Y., Boeckmans, J., Rodrigues, R. M., & He, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108353 · Cited by 31
Role of Interleukin-22 in chronic liver injury
do Carmo, R. F., Cavalcanti, M. S. M., & de Moura, P. M. M. F. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.023 · Cited by 31
Li, L., Xia, Y., Ji, X., Wang, H., Zhang, Z., Lu, P., Ding, Q., Wang, D., & Liu, M. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112801 · Cited by 33
Crucial role of T cells in NAFLD-related disease: A review and prospect
Mao, T., Yang, R. X., Luo, Y., & He, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051076 · Cited by 33
Inflammatory processes involved in NASH-related hepatocellular carcinoma
Cannito, S., Dianzani, U., Parola, M., Albano, E., & Sutti, S. (2023) · Bioscience Reports · doi:10.1042/bsr20221271 · Cited by 31
Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis
Wan, M., Han, J., Ding, L., Hu, F., & Gao, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.604894 · Cited by 30
Alchera, E., Rolla, S., Imarisio, C., Bardina, V., Valente, G., Novelli, F., & Carini, R. (2016) · Translational research · doi:10.1016/j.trsl.2016.11.009 · Cited by 29
Self-citationŚwiderska, M., Jaroszewicz, J., Stawicka, A., Parfieniuk‐Kowerda, A., Chabowski, A., & Flisiak, R. (2017) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2017.68466 · Cited by 28
The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies
Lücke, J., Sabihi, M., Zhang, T., Bauditz, L. F., Shiri, A. M., Giannou, A. D., & Huber, S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00854-z · Cited by 33
Zhang, N., Yao, H., Zhang, Z., Li, Z., Chen, X., Zhao, Y., Ju, R., He, J., Pan, H., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131588 · Cited by 35
Liu, J., Ding, M., Bai, J., Luo, R., Liu, R., Qu, J., & Li, X. (2023) · iMeta · doi:10.1002/imt2.76 · Cited by 25
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
Abdelnabi, M. N., Molina, M. F., Soucy, G., Trinh, V. Q., Bédard, N., Mazouz, S., Jouvet, N., Dion, J., Tran, S., Bilodeau, M., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.08.001 · Cited by 27
The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03595-1 · Cited by 24
Harnessing IL-22 for metabolic health: promise and pitfalls
Sajiir, H., Ramm, G. A., Macdonald, G. A., McGuckin, M. A., Prins, J. B., & Hasnain, S. Z. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.10.016 · Cited by 26
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Yu, S., Wang, J., Zheng, H., Wang, R., Johnson, N. L., Li, T., Li, P., Lin, J., Li, Y., Jin, Y., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s377768 · Cited by 29
Vonghia, L., Herck, M. A. V., Weyler, J., & Francque, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00563 · Cited by 25
Zhang, H., Xiong, Y., Yang, C., Zhan, Q., Fu, Y., Luo, H., & Luo, H. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13352 · Cited by 22
Rubio, T., Felipo, V., Tarazona, S., Pastorelli, R., Escudero‐García, D., Tosca-Cuquerella, J., Urios, A., Conesa, A., & Montoliu, C. (2021) · Scientific Reports · doi:10.1038/s41598-020-80941-7 · Cited by 20
Feng, D. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.003 · Cited by 18
Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis
Wang, X., Ji, D., Zhu, B., Jiang, S., Han, L., Wang, Y., Mai, H., Xu, S., Jiang, H., Wang, G., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104009 · Cited by 18
van der Zande, H. J. P., Brombacher, E. C., Lambooij, J. M., Pelgrom, L. R., Zawistowska‐Deniziak, A., Patente, T. A., Heieis, G. A., Otto, F., Ozir‐Fazalalikhan, A., Yazdanbakhsh, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157948 · Cited by 21
Matsumoto, K., Kikuchi, K., Kuniyoshi, N., Tsunashima, H., Sekine, K., Mabuchi, M., Doi, S., Zen, Y., & Miyakawa, H. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3204-19 · Cited by 16
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Torosian, K., Lal, E., Kavanaugh, A., Loomba, R. S., Ajmera, V. H., & Gumá, M. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152165 · Cited by 17
Popov, J., Despot, T., Rodriguez, D. A., Khan, I. I., Mech, E., Khan, M. A., Bojadzija, M., & Pai, N. (2024) · Nutrients · doi:10.3390/nu16111668 · Cited by 16
Nguyen, H. H., Talbot, J., Li, D., Raghavan, V., & Littman, D. R. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000528 · Cited by 15
Learning Representations of Inorganic Materials from Generative Adversarial Networks
Hu, T., Song, H., Jiang, T., & Li, S. (2020) · Symmetry · doi:10.3390/sym12111889 · Cited by 17
Crohn’s Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Aggarwal, M., Garg, R., Parthasarthy, G., Nowacki, A. S., Padival, R., McCullough, A. J., Qazi, T., Click, B. H., Rieder, F., & Cohen, B. L. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07562-0 · Cited by 16
Yoon, J.-S., & Lee, C.-W. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00883-0 · Cited by 14
Geng, Y., Liu, Z., Hu, R., Ma, W., Wu, X., Dong, H., Song, K., Xu, X., Huang, Y., Li, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01236-9 · Cited by 16
The double roles of T cell-mediated immune response in the progression of MASLD
Li, Z., Wang, S., Xu, Q., Su, X., Wang, Y., Wang, L., & Zhang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116333 · Cited by 19
Immune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 16
Metadata
- Authors
- Rolla, S., Alchera, E., Imarisio, C., Bardina, V., Valente, G., Cappello, P., Mombello, C., Follenzi, A., Novelli, F., & Carini, R.
- Affiliations
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- ORCID
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2015-12-17
- Volume
- 130
- Issue
- 3
- Pages
- 193-203
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2196060005
- Cited by
- 158
- References
- 80
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 15 · 2023: 20 · 2022: 23 · 2021: 23 · 2020: 16 · 2019: 12 · 2018: 9 · 2017: 9 · 2016: 6
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- nonalcoholic steatohepatitis, IL-17, IL-22, Th17 cells, Th22 cells, CD4+ T helper cells, liver fibrosis, steatosis, methionine-choline-deficient diet, palmitate, JNK signaling, PI3K/Akt signaling, PTEN, CCL20, interleukin-6, TNF-α, TGF-beta, IL-17 inhibitors
- MeSH terms
- Interleukin-22, Animals, Disease Models, Animal, T-Lymphocytes, Helper-Inducer, Interleukins, Liver, Male, Mice, Inbred C57BL, Interleukin-17, T-Lymphocytes, Regulatory, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.